3/21
08:41 am
brns
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/20
06:37 pm
brns
Barinthus Biotherapeutics GAAP EPS of -$1.55 misses by $0.25, revenue of $14.97M [Seeking Alpha]
Low
Report
Barinthus Biotherapeutics GAAP EPS of -$1.55 misses by $0.25, revenue of $14.97M [Seeking Alpha]
3/20
07:22 am
brns
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Low
Report
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
3/5
05:46 pm
brns
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Medium
Report
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
3/5
05:46 pm
brns
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Medium
Report
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
1/13
08:04 am
brns
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
High
Report
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
1/10
08:00 am
brns
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
High
Report
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update